Zai Lab Limited
A biopharmaceutical company that develops and brings to market medicines for cancer, immunology, neuroscience, and infectious disease, with a presence in both China and the United States. Founded in 2014 by Dr. Samantha Du, often called the 'godmother of China's biotech industry,' it was built to bring global medical innovations to Chinese patients faster. Its name comes from the Chinese character 'zài' (在), meaning 'to be' or 'to exist' — a nod to being present in patients' lives.
American Depositary Receipt
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Chen Yu | 13GPassive | 5.3% | 59.13M | Jun 11, 2026 |
| TCG Crossover GP II, LLC | 13GPassive | 2.6% | 29.57M | Jun 11, 2026 |
| TCG Crossover Fund II, L.P. | 13GPassive | 2.6% | 29.57M | Jun 11, 2026 |
| TCG Crossover GP III, LLC | 13GPassive | 2.6% | 29.57M | Jun 11, 2026 |
| TCG Crossover Fund III, L.P. | 13GPassive | 2.6% | 29.57M | Jun 11, 2026 |
| RA Capital Management, L.P. | 13GPassive | 5.2% | 57.44M | Apr 6, 2026 |
| Peter Kolchinsky | 13GPassive | 5.2% | 57.44M | Apr 6, 2026 |
| Rajeev Shah | 13GPassive | 5.2% | 57.44M | Apr 6, 2026 |
| RA Capital Healthcare Fund, L.P. | 13GPassive | 5.2% | 57.44M | Apr 6, 2026 |
| RTW Investments, LP | 13GPassive | 6.3% | 69.59M | Feb 17, 2026 |